Literature DB >> 11039126

Serum osteocalcin has limited usefulness as a diagnostic marker for rickets.

E D Daniels1, J M Pettifor, G P Moodley.   

Abstract

UNLABELLED: Serum alkaline phosphatase (AP), the bone fraction of which is secreted by osteoblasts, is elevated in rickets. Both normal and elevated levels of serum osteocalcin (OC), a bone-specific marker secreted by osteoblasts, have been reported in rickets. Expression of the OC gene is enhanced by 1,25-dihydroxyvitamin D (1,25(OH)2D) in experimental models. This study assessed serum OC levels in 14 controls and 41 patients with active rickets divided into a phosphopenic (n = 20) and a calciopenic (n = 21) group. Phosphopenic subjects were older (9.5 versus 5.7 years, P = 0.03) with higher median serum calcium level (2.35 versus 2.16 mmol/l, P = 0.0002) and serum 25-hydroxyvitamin D level (15.4 versus 10.4 ng/l, P = 0.003); and lower serum phosphate (0.80 versus 1.51 mmol/l, P = 0.0001), serum 1,25(OH)2D (43.0 versus 95.6 pg/ml, P = 0.0001) and intact serum parathyroid hormone level (45.0 versus 141.5 ng/l, P = 0.01) than calciopenic subjects. There were no differences in median serum AP (774 versus 1430 IU/l, P = 0.17) and OC (14.5 versus 13.4 ng/ml, P = 0.6) between the two groups. The mean OC value for the 41 rickets subjects was 15.1 +/- 6.2 ng/ml and 17.4 +/- 7.8 ng/ml for the 14 control subjects. In the face of markedly elevated serum AP levels in the rickets subjects, all of the serum OC values in the study fell within two standard deviations of the mean for normals. There was no association between serum OC and 1,25-(OH)2D in either the phosphopenic or the calciopenic group.
CONCLUSION: These results show that serum osteocalcin levels are not elevated in all forms of active rickets and that, unlike serum alkaline phosphatase, serum osteocalcin cannot be used in the diagnosis of rickets.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11039126     DOI: 10.1007/pl00008336

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  7 in total

1.  High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K.

Authors:  A F Schilling; C Mülhausen; W Lehmann; R Santer; T Schinke; J M Rueger; M Amling
Journal:  Osteoporos Int       Date:  2007-01-06       Impact factor: 4.507

2.  Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.

Authors:  Yuki Nagata; Yasuo Imanishi; Akira Ishii; Masafumi Kurajoh; Koka Motoyama; Tomoaki Morioka; Hiroshi Naka; Katsuhito Mori; Takami Miki; Masanori Emoto; Masaaki Inaba
Journal:  Endocrine       Date:  2011-08-06       Impact factor: 3.633

Review 3.  The assessment of fracture risk.

Authors:  Aasis Unnanuntana; Brian P Gladnick; Eve Donnelly; Joseph M Lane
Journal:  J Bone Joint Surg Am       Date:  2010-03       Impact factor: 5.284

4.  Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.

Authors:  Todd T Brown; Allison C Ross; Norma Storer; Danielle Labbato; Grace A McComsey
Journal:  Antivir Ther       Date:  2011

Review 5.  Vitamin D Status in South Africa and Tuberculosis.

Authors:  Vanessa Meyer; Tamsyn Jacki Jeffery; Liza Bornman
Journal:  Lung       Date:  2015-08-26       Impact factor: 2.584

6.  Vitamin D Deficiency and Its Health Consequences in Africa.

Authors:  Ann Prentice; Inez Schoenmakers; Kerry S Jones; Landing M A Jarjou; Gail R Goldberg
Journal:  Clin Rev Bone Miner Metab       Date:  2009

Review 7.  Pediatric vitamin D and calcium nutrition in developing countries.

Authors:  Philip R Fischer; Tom D Thacher; John M Pettifor
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 9.306

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.